Merck

YTD

ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.

CEO

Robert M. Davis

CEORobert M. Davis

Employees

75,000

Employees75,000

Headquarters

Rahway, New Jersey

HeadquartersRahway, New Jersey

Founded

1891

Founded1891

Employees

75,000

Employees75,000

MRK Key Statistics

Market cap

225.37B

Market cap225.37B

Price-Earnings ratio

13.00

Price-Earnings ratio13.00

Dividend yield

3.56%

Dividend yield3.56%

Average volume

19.07M

Average volume19.07M

High today

$90.14

High today$90.14

Low today

$87.67

Low today$87.67

Open price

$88.25

Open price$88.25

Volume

12.39M

Volume12.39M

52 Week high

$134.63

52 Week high$134.63

52 Week low

$81.04

52 Week low$81.04

MRK News

Simply Wall St 2d

Merck Gains EC Approval For CAPVAXIVE® Amid Recent 7% Share Price Dip

has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vacc...

TipRanks 3d

Merck announces EC approved Capvaxive pneumococcal vaccine

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or Pneumococcal 21-val...

Benzinga 3d

Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment

Merck & Co Inc MRK and Jiangsu Hengrui Pharmaceuticals Co., Ltd on Tuesday entered into an exclusive license agreement for HRS-5346, an investigational oral sma...

Analyst ratings

67%

of 27 ratings

Buy

66.7%

Hold

33.3%

Sell

More MRK News

TipRanks 3d

Merck Becomes Latest Big Pharma Stock to Tap China with $2B Heart Disease Drug Rights Deal

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of...

Seeking Alpha 4d

Merck inks a licensing deal worth nearly $2B with China’s Jiangsu Hengrui

Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to jointly develop and commercial...